IM37
Anti-MMP-9 (Ab-3) Mouse mAb (56-2A4)
liquid, clone 56-2A4, Calbiochem®
Sinónimos:
Anti-Gelatinase B, Anti-92 kDa Gelatinase, Anti-Matrix Metalloproteinase 9
Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
About This Item
UNSPSC Code:
12352203
NACRES:
NA.41
Productos recomendados
biological source
mouse
Quality Level
antibody form
purified antibody
antibody product type
primary antibodies
clone
56-2A4, monoclonal
form
liquid
contains
≤0.1% sodium azide as preservative
species reactivity
human, rabbit, rat, guinea pig
should not react with
hamster, mouse, bovine
manufacturer/tradename
Calbiochem®
storage condition
OK to freeze
avoid repeated freeze/thaw cycles
isotype
IgG1
shipped in
wet ice
storage temp.
−20°C
target post-translational modification
unmodified
Gene Information
human ... MMP9(4318)
General description
Purified mouse monoclonal antibody (see application references). Recognizes both the ~92 kDa latent and the ~83 kDa active forms of MMP-9.
Recognizes the ~92 kDa latent and the ~83 kDa active forms of MMP-9 in breast carcinoma tissue.
This Anti-MMP-9 (Ab-3) Mouse mAb (56-2A4) is validated for use in Frozen Sections, Immunoblotting, Paraffin Sections for the detection of MMP-9 (Ab-3).
Immunogen
Human
a synthetic peptide corresponding to amino acids 626-644 of human MMP-9
Application
Frozen Sections (see application references)
Immunoblotting (1 g/ml)
Paraffin Sections (see application references)
Packaging
Please refer to vial label for lot-specific concentration.
Warning
Toxicity: Standard Handling (A)
Physical form
In 100 mM sodium phosphate buffer, 0.1% BSA, pH 7.0
Reconstitution
Following initial thaw, aliquot and freeze (-20°C).
Analysis Note
Negative Control
MMP-2 protein (Cat. Nos. PF023 or PF037)
MMP-2 protein (Cat. Nos. PF023 or PF037)
Positive Control
MMP-9 protein (Cat. Nos. PF024 or PF038) or breast carcinoma tissue
MMP-9 protein (Cat. Nos. PF024 or PF038) or breast carcinoma tissue
Other Notes
Cottam, D.W. and Rees, R.C. 1993. Intl. J. Oncol.2, 861.
Stetler-Stevenson, W.G., et al. 1993. FASEB J.7, 1434.
Okada, Y., et al., 1992. J. Biol. Chem.267, 21712.
Woessner, J.F. 1991. FASEB J.5, 2145.
Liotta, L.A. and Stetler-Stevenson, W.G. 1990. in Seminars in Cancer Biology, ed. M.M. Gottesman. Vol. 1, 99.
Stetler-Stevenson, W.G., et al. 1993. FASEB J.7, 1434.
Okada, Y., et al., 1992. J. Biol. Chem.267, 21712.
Woessner, J.F. 1991. FASEB J.5, 2145.
Liotta, L.A. and Stetler-Stevenson, W.G. 1990. in Seminars in Cancer Biology, ed. M.M. Gottesman. Vol. 1, 99.
This antibody does not react with MMP-1, MMP-2, MMP-3 or MMP-13. Antibody should be titrated for optimal results in individual systems.
Legal Information
Manufactured by Daiichi Fine Chemical Co., Ltd. Not available for sale in Japan.
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
¿No encuentra el producto adecuado?
Pruebe nuestro Herramienta de selección de productos.
Storage Class
10 - Combustible liquids
wgk_germany
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable
Certificados de análisis (COA)
Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»
¿Ya tiene este producto?
Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.
Shinichiro Fujimoto et al.
Journal of the American College of Cardiology, 52(23), 1847-1857 (2008-11-29)
This study sought to evaluate the feasibility of noninvasive detection of matrix metalloproteinase (MMP) activity in experimental atherosclerosis using technetium-99m-labeled broad matrix metalloproteinase inhibitor (MPI) and to determine the effect of dietary modification and statin treatment on MMP activity. The
Satoru Ohshima et al.
Journal of the American College of Cardiology, 55(12), 1240-1249 (2010-03-20)
Technetium-99m-labeled matrix metalloproteinase inhibitor (MPI) was used for the noninvasive assessment of matrix metalloproteinase (MMP) activity in atherosclerotic plaques after minocycline (MC) intervention. MMP activity in atherosclerosis contributes to plaque instability. Some antimicrobial agents may attenuate MMP activity. Atherosclerotic lesions
Fábio Montico et al.
Anatomical record (Hoboken, N.J. : 2007), 296(11), 1758-1767 (2013-10-10)
The influence of senescence and hormone replacement on the onset of pathologic processes in the prostate is not yet fully understood. The aim was to identify the immunoreactivity and protein levels of molecules involved in cell proliferation, tissue remodeling and
Nezam Haider et al.
Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology, 16(5), 753-762 (2009-08-08)
Macrophage apoptosis and MMP activity contribute to vulnerability of atherosclerotic plaques to rupture. By employing molecular imaging techniques, we investigated if apoptosis and MMP release are interlinked. Atherosclerosis was produced in rabbits receiving high-cholesterol diet (HC), who underwent dual radionuclide
Jonathan M Fahey et al.
The Journal of biological chemistry, 293(14), 5345-5359 (2018-02-15)
Endogenous nitric oxide (NO) generated by inducible NO synthase (iNOS) promotes glioblastoma cell proliferation and invasion and also plays a key role in glioblastoma resistance to chemotherapy and radiotherapy. Non-ionizing photodynamic therapy (PDT) has anti-tumor advantages over conventional glioblastoma therapies.
Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.
Póngase en contacto con el Servicio técnico